Oakbrook Investments LLC lowered its position in shares of Celgene Co. (NASDAQ:CELG) by 13.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,353 shares of the biopharmaceutical company’s stock after selling 5,525 shares during the quarter. Oakbrook Investments LLC’s holdings in Celgene were worth $5,009,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in CELG. Savant Capital LLC raised its position in shares of Celgene by 5.9% during the 1st quarter. Savant Capital LLC now owns 2,330 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 130 shares during the period. Wimmer Associates 1 LLC raised its position in shares of Celgene by 60.3% during the 1st quarter. Wimmer Associates 1 LLC now owns 4,305 shares of the biopharmaceutical company’s stock worth $536,000 after purchasing an additional 1,620 shares during the period. Mason Street Advisors LLC raised its position in shares of Celgene by 1.4% during the 1st quarter. Mason Street Advisors LLC now owns 107,509 shares of the biopharmaceutical company’s stock worth $13,377,000 after purchasing an additional 1,465 shares during the period. LBA Wealth Management LLC raised its position in shares of Celgene by 5.2% during the 1st quarter. LBA Wealth Management LLC now owns 7,061 shares of the biopharmaceutical company’s stock worth $879,000 after purchasing an additional 350 shares during the period. Finally, Envestnet Asset Management Inc. raised its position in shares of Celgene by 1.5% during the 1st quarter. Envestnet Asset Management Inc. now owns 151,184 shares of the biopharmaceutical company’s stock worth $18,810,000 after purchasing an additional 2,297 shares during the period. Hedge funds and other institutional investors own 79.84% of the company’s stock.

A number of analysts have recently weighed in on the company. UBS cut Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 price target on the stock. in a research report on Thursday, October 26th. BMO Capital Markets dropped their price target on Celgene from $163.00 to $148.00 and set an “outperform” rating on the stock in a research report on Friday, October 27th. BTIG Research reiterated a “neutral” rating on shares of Celgene in a research report on Tuesday, September 5th. Jefferies Group reiterated a “buy” rating and set a $160.00 price target on shares of Celgene in a research report on Friday, September 15th. Finally, Robert W. Baird cut Celgene from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $162.00 to $136.00 in a research report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $136.21.

In other news, insider Terrie Curran sold 1,727 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares in the company, valued at $564,768.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.95% of the stock is owned by corporate insiders.

Shares of Celgene Co. (CELG) opened at $107.06 on Wednesday. Celgene Co. has a 52-week low of $94.55 and a 52-week high of $147.17. The company has a market capitalization of $86,140.35, a price-to-earnings ratio of 17.09, a PEG ratio of 0.84 and a beta of 1.78. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter in the prior year, the firm earned $1.58 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. sell-side analysts forecast that Celgene Co. will post 6.68 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Oakbrook Investments LLC Cuts Holdings in Celgene Co. (CELG)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/oakbrook-investments-llc-cuts-holdings-in-celgene-co-celg/1773833.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.